Clinical Trial

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the treatment of patients with advanced or metastatic cancer in whom there is no available standard therapeutic option.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-09-16; most recent amendment 2025-11-20.
Status change: Not Yet Recruiting → Recruiting 2023-02-22
Trial Details
NCT Number NCT05547321
Lead Sponsor Oncomatryx Biopharma S.L.
Collaborators: Centro de Investigación del Cáncer Universidad de Salamanca, CTI Laboratory Services Spain, Anapharm Bioanalytics, Certara, Biotrial, Alcura Health España SA, Clinigen, Inc., Evidenze CRO, TFS Health Science, HistoOne, Opthimapharm
Conditions Advanced Solid Tumor
Enrollment 150 participants
Start Date 2022-10-20
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-25